On the basis of our experimental studies, FPCHN-30 could be used as a promising therapeutic delivery system for MDR-expressing breast cancer cells by sequential release of p-gp inhibitor and anticancer drug, and active targeting to FA receptors (Figure 1A and 1B). Here, PGP is linked to breast cancer.